s-adenosylhomocysteine

SAH (SAH (S-Adenosylhomocysteine)) is an inhibitor for the METTL3-METTL14 heterodimer complex (METTL3-14, IC50: 0.9 μM).

3-Deazaadenosine hydrochloride is an inhibitor of S-adenosylhomocysteine hydrolase (Ki: 3.9 µM). It has anti-inflammatory, anti-proliferative, and anti-HIV activity.

3-deazaneplanocin A (DZNeP)HCl, an analog of adenosine, is a competitive inhibitor of S-adenosylhomocysteine hydrolase with Ki of 50 pM.

Adenosine Dialdehyde (Periodate-oxidized adenosine) is a purine nucleoside analogue. Adenosine Dialdehyde is a potent inhibitor of S-Adenosylhomocysteine hydrolase (SAHH) (Ki=3.3 nM). Adenosine Dialdehyde exhibits potent anti-tumor activity in vivo.

3-Deazaadenosine (3-DAA) is a potent S-adenosylhomocysteine (SAH) hydrolase inhibitor. It inhibits methylation reactions by inducing intracellular SAH accumulation, exhibiting antiviral, anti-inflammatory, and immunomodulatory activities.

Aristeromycin (U 99468) is a broad-spectrum antiviral antibiotic that targets RNA viruses and is an inhibitor of S-adenosylhomocysteine hydrolase (AHCY).

SAHO is a sulfoxide form of the methyl donor S-(5'-adenosyl)-L-methionine chloride and a substrate for radical SAM enzymes.1It is reductively cleaved to S-adenosylhomocysteine , 5'-deoxyadenosine , and 5'-thioadenosine sulfenic acid by the radical SAM enzymes NosL or NosN. 1.Mandalapu, D., Ji, X., and Zhang, Q.Reductive cleavage of sulfoxide and sulfone by two radical S-adenosyl-L-methionine enzymesBiochemistry58(1)36-39(2019)

3-Deazaneplanocin A (DZNep) is a dual inhibitor of histone methyltransferase (EZH2) and S-adenosylhomocysteine hydrolase (AHCY) with antipoxidative activity that inhibits hepatic, renal, peritoneal, and airway fibrosis by inducing proteasomal degradation of its targets and reducing toxicity in animal models.

Aristeromycin diphosphate is an inhibitor of S-adenosylhomocysteine hydrolase (AHCY), inducing miR-26a and regulating oncogenic EZH2 expression, showing high inhibitory activity against AHCY, and causing growth inhibition of prostate cancer.

Adenosylhomocysteinase (SAHH; AHCY), a highly conserved enzyme, reversibly catalyzes S-adenosylhomocysteine (SAH) into adenosine and L-homocysteine. Its level in serum exosomes serves as a prognostic biomarker for HBV-LC patients [1] [2].

S-Adenosylhomocysteine (SAH) hydrolase is responsible for the reversible hydrolysis of SAH into adenosine and homocysteine. Inhibition of this enzyme leads to the accumulation of SAH within cells, thereby increasing the SAH to S-adenosylmethionine (SAM) ratio and subsequently inhibiting SAM-dependent methyltransferases. (−)-Neplanocin A, a potent and irreversible inhibitor of SAH hydrolase (Ki= 8.39 nM), exhibits significant antitumor activity against mouse leukemia L1210 cells and holds broad-spectrum antiviral properties. Its efficacy notably surpasses that of the reversible inhibitor 3-deazaneplanocin, especially in combating vesicular stomatitis, evidencing a higher potency with ID50 values of 0.07 μg/ml for Neplanocin A versus 0.3 μg/ml for 3-deazaneplanocin.

SAH (Standard) is a reference standard for research and analysis in studies involving SAH. SAH (S-Adenosylhomocysteine) belongs to the group of amino acid derivatives that are intermediates in the synthesis of adenosine and cysteine. SAH is an inhibitor of the METTL3-METTL14 heterodimeric complex (IC50=0.9 µM).SAH is a regulator of several metabolic pathways.